

June 15, 2023

| То | То |
|---------------------------------------|---|
| | |
| The Corporate Relations Department | The Listing Department |
| BSE Limited | National Stock Exchange of India Limited, |
| Phiroz Jeejeebhoy Towers, 25th Floor, | Exchange Plaza, |
| Dalal Street | Bandra Kurla Complex, Bandra (East) |
| Mumbai – 400001 | Mumbai – 400 051 |
| | |
| Code: 540222 | Code: LAURUSLABS |

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

Further to our intimation dated February 10, 2023, on the Inspection conducted by the United States Food & Drug Administration (USFDA) at our formulations manufacturing facility Unit–2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh from 6th February, 2023 to 10th February, 2023, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from USFDA.

This is for your information and record.

Yours faithfully, For Laurus Labs Limited

G. Venkateswar Reddy Company Secretary

Registered Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India. CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com



